Patents by Inventor Frank J. Gonzalez
Frank J. Gonzalez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10487363Abstract: Compositions and methods for the diagnosis, treatment, and prevention of neoplasia (e.g., colorectal cancer).Type: GrantFiled: January 23, 2014Date of Patent: November 26, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Soumen K. Manna, Kristopher W. Krausz, Frank J. Gonzalez
-
Patent number: 10233209Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.Type: GrantFiled: December 6, 2016Date of Patent: March 19, 2019Assignees: The United States of America, As represented by the Secretary, Department of Health and Human Services, The Penn State Research FoundationInventors: Frank J. Gonzalez, Changtao Jiang, Cen Xie, Andrew D. Patterson, Fei Li, James B. Mitchell, Shantu Amin, Dhimant Desai
-
Publication number: 20180188254Abstract: Disclosed herein are methods of diagnosing and treating a malignant adrenocortical tumor, including adrenocortical carcinoma. In some examples, methods of diagnosing a malignant adrenocortical tumor include measuring creatine riboside, L-tryptophan, N?,N?,N?-trimethyl-L-lysine and 3-methylhistidine in a biological sample obtained from a subject with an adrenocortical tumor and identifying an increase in creatine riboside and a decrease in L-tryptophan, N?,N?,N?-trimethyl-L-lysine and 3-methylhistidine in the biological sample when compared to a control or reference value for each molecule indicates a malignant adrenocortical tumor. Methods of treatment and evaluating the effectiveness of an agent for treating a malignant adrenocortical tumor are also disclosed. Additionally, kits, assays and devices for characterizing adrenocortical tumors are provided.Type: ApplicationFiled: June 29, 2016Publication date: July 5, 2018Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human ServInventors: Dhaval T. Patel, Kristopher W. Krausz, Frank J. Gonzalez, Electron Kebebew, Matthew Thompson
-
Publication number: 20170152283Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.Type: ApplicationFiled: December 6, 2016Publication date: June 1, 2017Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Penn State Research FoundationInventors: Frank J. Gonzalez, Changtao Jiang, Cen Xie, Andrew D. Patterson, Fei Li, James B. Mitchell, Shantu Amin, Dhimant Desai
-
Patent number: 9540415Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.Type: GrantFiled: August 1, 2014Date of Patent: January 10, 2017Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Penn State Research FoundationInventors: Frank J. Gonzalez, Changtao Jiang, Cen Xie, Andrew D. Patterson, Fei Li, James B. Mitchell
-
Publication number: 20160159851Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.Type: ApplicationFiled: August 1, 2014Publication date: June 9, 2016Applicants: The United Sates of America, as represented by the Secretary, Department of Health and Human Service, The Penn State Research FoundationInventors: Frank J. Gonzalez, Changtao Jiang, Cen Xie, Andrew D. Patterson, Fei Li, James B. Mitchell, Shantu Amin, Dhimant Desai
-
Publication number: 20150344969Abstract: Compositions and methods for the diagnosis, treatment, and prevention of neoplasia (e.g., colorectal cancer).Type: ApplicationFiled: January 23, 2014Publication date: December 3, 2015Inventors: Soumen K. Manna, Kristopher W. Krausz, Frank J. Gonzalez
-
Publication number: 20110055943Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of bowl disease (BD). The invention provides BD-associated polynucleotide sequences whose expression is associated with BD. Provided herein are diagnostic compositions and methods for the detection of BD. The present invention provides monoclonal and polyclonal antibodies specific for the BD polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of BD.Type: ApplicationFiled: October 16, 2008Publication date: March 3, 2011Applicant: SALIX PHARMACEUTICALS, LTD.Inventors: Frank J. Gonzalez, Lorin Johnson, Xiaochao Ma
-
Patent number: 7682800Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.Type: GrantFiled: March 7, 2007Date of Patent: March 23, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Publication number: 20090318556Abstract: Disclosed herein are biomarkers for determining gamma radiation exposure by an animal or human. The biomarkers include 3-hydroxy-2-methylbenzoic acid 3-O-sulfate, N-hexanoylglycine, ?-thymidine, taurine, xanthine, xanthosine, 2?-deoxyuridine, 2?-deoxycytidine, 2?-deoxyxanthosine, or any salt, ion, or combination thereof. Also disclosed are methods for determining gamma radiation exposure by an animal or human, which include the step of measuring the amount of one or more biomarkers specific to gamma radiation in the biological fluid and correlating the amount of said biomarkers to the amount of gamma radiation exposure by the animal or human. Systems for determining gamma radiation exposure by an animal or human and methods of treating an animal or human for gamma radiation exposure are also disclosed.Type: ApplicationFiled: May 15, 2008Publication date: December 24, 2009Inventors: Jeffrey R. Idle, Frank J. Gonzalez, John B. Tyburski, Kristopher W. Krausz, Andrew David Patterson
-
Publication number: 20090280537Abstract: The present invention provides methods, compositions and kits for the detection of genetic polymorphisms or mutations of the dihydropyrimidine dehydrogenase deficiency (DPDD). The polymorphisms or mutations generally occur in the dihydropyrimidine dehydrogenase (DPD) gene in chromosome 1. Also provided are mutant forms of DPD.Type: ApplicationFiled: June 16, 2008Publication date: November 12, 2009Applicant: The Government of USA as Represented by the Secret ary of the Department of Health and Human ServiceInventors: Frank J. Gonzalez, Pedro Fernandez-Salguero
-
Patent number: 7524939Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.Type: GrantFiled: July 9, 2003Date of Patent: April 28, 2009Assignee: United States of America as represented by Department of Health and Human ServicesInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Patent number: 7402387Abstract: The present invention provides compositions, methods, and kits for the detection of genetic polymorphisms or mutations of the dihydropyrimidine dehydrogenase deficiency (DPDD). The polymorphisms or mutations generally occur in the dihydropyrimidine dehydrogenase (DPD) gene in chromosome 1. Also provided are mutant forms of DPD.Type: GrantFiled: August 3, 2004Date of Patent: July 22, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Frank J. Gonzalez, Pedro Fernandez-Salguero
-
Patent number: 7262018Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.Type: GrantFiled: September 14, 2004Date of Patent: August 28, 2007Assignee: National Institutes of HealthInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Patent number: 6908738Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.Type: GrantFiled: September 10, 2001Date of Patent: June 21, 2005Assignee: National Institute of HealthInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Patent number: 6787306Abstract: The present invention provides compositions, methods and kits for the detection of genetic polymorphisms or mutations related to dihydropyrimidine dehydrogenase deficiency (DPDD). The polymorphism or mutations generally occur in the dihydropyrimidine dehydrogenase DPD gene in chromosome 1. Also provided are mutant forms of DPD.Type: GrantFiled: October 28, 1999Date of Patent: September 7, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Frank J. Gonzalez, Pedro Fernandez-Salguero
-
Patent number: 6623960Abstract: The invention provides monoclonal antibodies to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.Type: GrantFiled: December 22, 1999Date of Patent: September 23, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Publication number: 20020115124Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C 19 levels in individuals relative to P450 2C19 levels in a control population.Type: ApplicationFiled: September 10, 2001Publication date: August 22, 2002Inventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Patent number: 6335428Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 1A2 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 1A2 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 1A2, and in methods of measuring p450 1A2 levels in individuals relative to p450 1A2 levels in a control population.Type: GrantFiled: April 8, 1999Date of Patent: January 1, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Harry V. Gelboin, Frank J. Gonzalez, Tian J. Yang
-
Patent number: 6323325Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2A6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2A6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in an individual relative to p450 2A6 levels in a control population.Type: GrantFiled: April 8, 1999Date of Patent: November 27, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Harry V. Gelboin, Frank J. Gonzalez